Mechanism of action of rituximab

Anti-Cancer Drugs

Volumn 12, Issue SUPPL. 2, 2001, Pages

  Maloney, D G ^a  

^a Fred Hutchinson Cancer Research Center   (United States)

Author keywords

ADCC; CD20; Monoclonal antibody; Rituximab

Indexed keywords

ANTINEOPLASTIC AGENT; CD20 ANTIGEN; MONOCLONAL ANTIBODY; RITUXIMAB;

ANTIBODY DEPENDENT CELLULAR CYTOTOXICITY; ANTIGEN EXPRESSION; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; CANCER INHIBITION; COMPLEMENT FIXATION; CONFERENCE PAPER; DRUG EFFICACY; DRUG POTENTIATION; EFFECTOR CELL; PRIORITY JOURNAL; TUMOR CELL CULTURE;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTIBODY-DEPENDENT CELL CYTOTOXICITY; ANTIGENS; ANTIGENS, CD20; ANTINEOPLASTIC AGENTS; CELL DIVISION; HUMANS; IMMUNOGLOBULIN G; LYMPHOMA; LYMPHOMA, NON-HODGKIN; PROTEIN BINDING;

EID: 0034951864     PISSN: 09594973     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (29)

1. Initial experience with treatment of human B cell lymphoma with anti-CD19 monoclonal antibody
2. Monoclonal antibody 1F5 (anti-CD20) serotherapy of human B cell lymphomas
3. Effects of CAMPATH-1 antibodies in vivo in patients with lymphoid malignancies: Influence of antibody isotype
4. A phase 1a clinical trial of LYM-1 monoclonal antibody serotherapy in patients with refractory B cell malignancies
5. Antiidiotype antibody therapy of B-cell lymphoma
6. Monoclonal antiidiotype antibody therapy of B-cell lymphoma: The addition of a short course of chemotherapy does not interfere with the antitumor effect nor prevent the emergence of idiotype-negative variant cells
7. Monoclonal anti-idiotype therapy of B-cell lymphoma
8. Final report on the safety and efficacy of retreatment with rituximab for patients with non-Hodgkin's lymphoma
9. Expression of human B cell-associated antigens on leukemias and lymphomas: A model of human B cell differentiation
10. Molecular cloning of the human B cell CD20 receptor predicts a hydrophobic protein with multiple transmembrane domains
11. Association of tyrosine and serine kinases with the B cell surface antigen CD20. Induction via CD20 of tyrosine phosphorylation and activation of phospholipase C-gamma 1 and PLC phospholipase C-gamma 2
12. Association of 75/80-kDa phosphoproteins and the tyrosine kinases Lyn, Fyn, and Lck with the B cell molecule CD20. Evidence against involvement of the cytoplasmic regions of CD20
13. Iodine-131-anti-B1 radioimmunotherapy for B-cell lymphoma
14. Radioimmunotherapy with iodine (131)I tositumomab for relapsed or refractory B-cell non-Hodgkin lymphoma: Updated results and long-term follow-up of the University of Michigan experience
15. Yttrium-90-labeled anti-CD20 monoclonal antibody therapy of recurrent B-cell lymphoma
16. Depletion of B cells in vivo by a chimeric mouse human monoclonal antibody to CD20
17. Overview of the clinical development of rituximab: First monoclonal antibody approved for the treatment of lymphoma
18. Activation of human B cell proliferation through surface Bp35 (CD20) polypeptides or immunoglobulin receptors
19. Antibodies reactive with the B1 molecule inhibit cell cycle progression but not activation of human B lymphocytes
20. Apoptosis of malignant human B cells by ligation of CD20 with monoclonal antibodies
21. Signaling events involved in anti-CD20-induced apoptosis of malignant human B cells
22. Chimeric anti-CD20 antibody (IDEC C2B8) is apoptotic and sensitizes drug-resistant human B cell lymphomas and AIDS related lymphomas to the cytotoxic effect of CDDP, VP-16 and toxins
23. Chimeric anti-CD20 (IDEC-C2B8) monoclonal antibody sensitizes a B cell lymphoma cell line to cell killing by cytotoxic drugs
24. Rituximab therapy in hematologic malignancy, patients with circulating blood tumor cells: Association with increased infusion-related side effects and rapid blood tumor clearance
25. Clonal selection of CD20-negative non-Hodgkin's lymphoma cells after treatment with anti-CD20 antibody rituximab
26. Association of serum Rituximab (IDEC-C2B8) concentration and anti-tumor response in the treatment of recurrent low-grade or follicular non-Hodgkin's lymphoma
27. Anti-idiotype antibodies can induce long-term complete remissions in non-Hodgkin's lymphoma without eradicating the malignant clone
28. Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: Half of patients respond to a four-dose treatment program
29. Treatment of patients with low-grade B-cell lymphoma with the combination of chimeric anti-CD20 monoclonal antibody and CHOP chemotherapy